FDA clears belzutifan-pembrolizumab combination to delay kidney cancer's return
New CapabilitiesA two-drug regimen becomes a new post-surgery option for high-risk clear cell kidney cancer
June 12th, 2026: FDA approves the belzutifan-pembrolizumab combinationNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Surgery removes the tumor. For many high-risk kidney cancer patients, it doesn't end the disease. On June 12, 2026, the U.S. Food and Drug Administration (FDA) approved pairing belzutifan with the immunotherapy pembrolizumab to keep these patients cancer-free for longer after their kidney is removed.
The approval rests on a 1,841-patient trial. Adding belzutifan to pembrolizumab cut the risk of the cancer returning or death by 28% compared with pembrolizumab alone. The benefit came with more side effects, so doctors now weigh longer disease control against higher toxicity.
Why it matters
For high-risk kidney cancer patients, surgery often isn't the end. This regimen lowers the odds the cancer comes back.
Questions about this story
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
Merck developed both drugs in the newly approved combination and ran the trial behind it.
The FDA reviews and approves new drugs and new uses for existing drugs in the United States.
Timeline
August 2021 June 2026
-
FDA approves the belzutifan-pembrolizumab combination
Latest ApprovalDrawing on the 1,841-patient LITESPARK-022 trial first reported at the 2026 ASCO genitourinary cancers meeting, the FDA clears the combination to delay recurrence after surgery.
-
Belzutifan approved for advanced kidney cancer
ApprovalThe FDA expands belzutifan to patients with advanced clear cell kidney cancer whose disease progressed after earlier treatment.
-
Pembrolizumab becomes a post-surgery standard
ApprovalBased on the KEYNOTE-564 trial, the FDA approves pembrolizumab alone after kidney removal for high-risk patients. It later showed patients lived longer.
-
Belzutifan wins its first approval
ApprovalThe FDA clears belzutifan for tumors tied to von Hippel-Lindau disease. It is the first drug to block the HIF-2-alpha protein, a target long thought undruggable.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
Adjuvant sunitinib approval (2017)
The FDA approved sunitinib after surgery for high-risk kidney cancer based on the S-TRAC trial. The drug delayed recurrence but never showed patients lived longer. Side effects were heavy.
Many oncologists hesitated to prescribe it. Adoption stayed low despite the approval.
It became a cautionary case that a delay in recurrence does not always translate into longer life or wide use.
It shows why the pending survival data for belzutifan-pembrolizumab matters so much. A recurrence benefit alone may not be enough to win over doctors.
Adjuvant pembrolizumab approval (2021)
The FDA approved pembrolizumab alone after surgery for high-risk kidney cancer, based on the KEYNOTE-564 trial. Years later, follow-up showed patients on the drug lived longer than those on placebo.
It became the first post-surgery treatment to gain traction in kidney cancer in years.
It set the survival benchmark and the backbone that newer combinations, including this one, are built on.
The new combination adds belzutifan to this exact drug. Its value depends on beating pembrolizumab alone, the standard it builds on.
Belzutifan drugs an 'undruggable' target (2021)
The FDA approved belzutifan for tumors tied to von Hippel-Lindau disease. It was the first drug to block HIF-2-alpha, a protein that drives clear cell kidney cancer and was long considered impossible to target with a pill.
It gave patients with a rare inherited cancer syndrome a non-surgical option.
It opened a new line of attack on kidney cancer that Merck has since tested across multiple settings.
This combination pushes that mechanism into earlier, more common disease, pairing it with immunotherapy right after surgery.
